Featured Research

from universities, journals, and other organizations

Botulinum toxin provides clinically meaningful benefit for idiopathic OAB patients

Date:
April 19, 2010
Source:
European Association of Urology
Summary:
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. Botox may provide a minimally invasive effective treatment.

Treatment options for idiopathic OAB (IOAB) patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple (GB) and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

The results were presented recently at the Anniversary EAU Congress in Barcelona.

Chris Chapple: "IOAB patients with urinary urgency incontinence (UUI) whose symptoms are not adequately managed with anticholinergic therapy were recruited. Patients were randomised to receive BOTOX® 50U, 100U, 150U, 200U or 300U or placebo. This was administered as intradetrusor injections."

Patients were followed for 36 weeks post-treatment with assessments including 7-day bladder diary, post void residual urine volume (PVR), health-related quality of life (HRQOL) questionnaires and urodynamics.

Chris Chapple: "We were happy to see durable and clinically meaningful efficacy for all BOTOX® dose groups of 100U and above with significant reductions from baseline compared to placebo in patient symptoms, including being incontinence-free."

Dose response was identified in efficacy parameters; however a UUI analysis demonstrated minimal additional efficacy at BOTOX® doses above 150U and several HRQOL measures showed minimal incremental benefit above 100U.

Safety findings primarily related to local pharmacological effects on the bladder resulting in dose dependant increases in PVR. Adverse events significantly higher in BOTOX® dose groups compared to placebo were UTI and urinary retention; the proportion of patients using clean intermittent catheterisation (CIC) increased with dose. Dose response was identified in safety parameters, particularly in the proportion of patients having a PVR ≥ 200mL, a threshold associated with considerable increases in the use of CIC and adverse events such as urinary tract infection and urinary retention.

"This double-blind, placebo-controlled study demonstrated that BOTOX® provides a clinically meaningful benefit. The benefit / risk ratio has been evaluated over a broad range of BOTOX® doses in the idiopathic OAB population and doses of 100U -- 150U provide the appropriate benefit / risk balance. The clinically meaningful benefit is balanced with dose-dependant PVR elevation" Prof. Chapple concluded.


Story Source:

The above story is based on materials provided by European Association of Urology. Note: Materials may be edited for content and length.


Cite This Page:

European Association of Urology. "Botulinum toxin provides clinically meaningful benefit for idiopathic OAB patients." ScienceDaily. ScienceDaily, 19 April 2010. <www.sciencedaily.com/releases/2010/04/100419113703.htm>.
European Association of Urology. (2010, April 19). Botulinum toxin provides clinically meaningful benefit for idiopathic OAB patients. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2010/04/100419113703.htm
European Association of Urology. "Botulinum toxin provides clinically meaningful benefit for idiopathic OAB patients." ScienceDaily. www.sciencedaily.com/releases/2010/04/100419113703.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) — West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) — A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) — Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) — Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins